Company Profile

Biofrontera Inc Stock Price, News & Catalysts

Ticker:
BFRI
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

0.57 USD (-4.97%)

Close

Last updated: November 19, 2026

13.2M USD

Market cap

Why the stock is moving

As of Nov 19, 2026, BFRI closed down 4.97% at $0.5700. No new same-company headline was identified in the current news window.

Company overview

Dermatology Photodynamic Therapy

Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States. Its principal platform combines the topical photosensitizer Ameluz with RhodoLED red-light illumination systems.

Actinic Keratosis Franchise

Ameluz is established in actinic keratosis, a precancerous skin condition, and Biofrontera is pursuing broader treatment fields and body locations through supplemental regulatory development.

Superficial Basal-Cell Carcinoma

The FDA approved Ameluz photodynamic therapy for superficial basal-cell carcinoma in September 2026, adding the platform's first cancerous skin-tumor indication in the United States.

Integrated Commercial Platform

Biofrontera markets Ameluz through a specialist dermatology sales organization and supplies the companion RhodoLED lamps used to activate the therapy. The same commercial infrastructure supports both existing and new indications.

Future catalysts

  • Commercial rollout of Ameluz photodynamic therapy for superficial basal-cell carcinoma from late fourth-quarter 2026 into the first quarter of 2027.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Biofrontera Inc (BFRI)?

Biofrontera Inc (BFRI) most recently closed at 0.57 USD, a -4.97% move versus the previous session.

What is the market cap of Biofrontera Inc (BFRI)?

Biofrontera Inc currently has a market capitalization of 13.2M USD on BioPharmSignal.

What does Biofrontera Inc do?

Dermatology Photodynamic Therapy Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States. Its principal platform combines the topical photosensitizer Ameluz with RhodoLED red-light illumination systems. Actinic Keratosis Franchise Ameluz is established in actinic keratosis, a precancerous skin condition, and...

On which exchange is BFRI stock listed?

Biofrontera Inc (BFRI) is associated with NASDAQ, United States, Biopharma.

What is Dermatology?

Dermatology Photodynamic Therapy Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States.

Which conditions is Biofrontera Inc targeting with Dermatology?

Biofrontera Inc is associated with cancer therapeutics, dermatology based on its company overview and current catalyst commentary.

How does Biofrontera Inc describe recent progress with Dermatology?

Commercial rollout of Ameluz photodynamic therapy for superficial basal-cell carcinoma from late fourth-quarter 2026 into the first quarter of 2027.

What is Photodynamic?

Dermatology Photodynamic Therapy Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States.